Meldoz (Alendronate Sodium Trihydrate)

Alendronate binds to hydroxyapatite on bone surfaces and is taken up by osteoclasts during bone resorption. Inside the cell it inhibits farnesyl pyrophosphate synthase, a key enzyme in the mevalonate pathway, leading to osteoclast apoptosis and a net reduction in bone breakdown.

The specific dose of Meldoz is determined by the prescribing clinician based on the patient’s condition, renal function, and other individual factors. Healthcare providers set the appropriate strength and dosing schedule according to current clinical guidelines.

Safety data for alendronate in pregnancy and lactation are limited. It is generally advised to avoid use unless the potential benefit justifies the potential risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Meldoz (alendronate) is a first‑line oral bisphosphonate, offering a well‑established efficacy profile for reducing vertebral and hip fractures. Compared with newer agents such as denosumab or romosozumab, alendronate is generally less costly and administered orally, but may have a higher incidence of gastrointestinal side effects.

Meldoz should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and do not store in humid environments such as bathrooms.

Meldoz is taken orally, usually once weekly or once monthly, with a full glass of plain water on an empty stomach. Patients should remain upright for at least 30 minutes after dosing and avoid eating, drinking, or taking other medications during that period.

Serious risks include esophageal ulceration or erosion, osteonecrosis of the jaw, and atypical femur fractures. Patients should report persistent throat pain, jaw discomfort after dental procedures, or any unusual thigh or groin pain to their healthcare provider promptly.

Meldoz is contraindicated in patients with known hypersensitivity to alendronate or other bisphosphonates, those with severe renal impairment (creatinine clearance <30 mL/min), and individuals who cannot remain upright for at least 30 minutes after dosing. It should also be avoided in patients with esophageal disorders that delay emptying.